Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01648023 · ClinicalTrials.gov registry record · Phase 2
Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin
A Phase 2 study, sponsored by Robert C. Martin.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT01648023 is a Phase 2 study that has completed, run by Robert C. Martin. The registered enrollment target is 49 participants.
The verdict
NCT01648023, a Phase 2 study, has completed, sponsored by Robert C. Martin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if the combination of trans-arterial chemoembolization (LC or ONCOZENE BEAD) plus infusional chemotherapy is safe and more effective than just receiving the infusional chemotherapy alone.
Interventions
- DEVICE LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo
- DRUG Gem-Cis or Gem-Carbo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2012-07 |
| Est. Completion | 2019-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01648023
The ClinicalTrials.gov registry entry for NCT01648023 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Robert C. Martin, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo is the first listed.
NCT01648023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01648023 about?
NCT01648023 is a clinical study titled "Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin". The purpose of this study is to find out if the combination of trans-arterial chemoembolization (LC or ONCOZENE BEAD) plus infusional chemotherapy is safe and more effective than just receiving the infusional chemotherapy alone.
What is the current status of trial NCT01648023?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2012-07. Estimated completion is 2019-09.
What interventions are being tested in trial NCT01648023?
The interventions under investigation include: LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo (DEVICE), Gem-Cis or Gem-Carbo (DRUG).
Who is sponsoring clinical trial NCT01648023?
This trial is sponsored by Robert C. Martin, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.